Form 4: United Therapeutics CFO Executes Stock Option Plan

CFO James Edgemond exercised 10,000 stock options and sold the resulting shares under a pre-established Rule 10b5-1 trading plan.

Summary

• CFO James Edgemond exercised 10,000 stock options at a strike price of $117.76.
• Following the exercise, the reporting person sold all 10,000 shares in multiple tranches on June 11, 2026.
• The sales were executed at weighted average prices ranging from $542.94 to $551.83 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on October 31, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction was executed under a pre-planned 10b5-1 arrangement and represents standard executive financial management.

Positives

• The transaction was pre-planned under a Rule 10b5-1 plan, indicating the sale was not based on non-public information.
• The exercise of options demonstrates the executive's participation in the company's long-term equity incentive program.

Negatives

• The executive reduced their direct beneficial ownership of common stock by 10,000 shares.

Risks

• None identified; this is a routine disclosure of executive equity transactions.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is standard practice for corporate executives to manage personal liquidity and diversify holdings, and generally does not signal a change in company fundamentals.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives to avoid potential conflicts of interest regarding insider trading regulations.
• The volume of shares sold is consistent with typical executive compensation and divestment patterns for a company of this market capitalization.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-planned and executed in accordance with regulatory requirements.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

United Therapeutics, UTHR, Insider Trading, Form 4, CFO, Stock Options, Rule 10b5-1